首页> 外文期刊>Biomarker Insights >Quantitative Appraisal of Ventricular Cerebrospinal Fluid Biomarkers in Neuropathologically Diagnosed Parkinson's Disease Cases Lacking Alzheimer's Disease Pathology:
【24h】

Quantitative Appraisal of Ventricular Cerebrospinal Fluid Biomarkers in Neuropathologically Diagnosed Parkinson's Disease Cases Lacking Alzheimer's Disease Pathology:

机译:在缺乏阿尔茨海默氏病病理的神经病理学诊断为帕金森氏病的病例中对心室脑脊液生物标志物的定量评估:

获取原文

摘要

Identifying biomarkers that distinguish Parkinson's disease (PD) from normal control (NC) individuals has the potential to increase diagnostic sensitivity for the detection of early-stage PD. A previous proteomic study identified potential biomarkers in postmortem ventricular cerebrospinal fluid (V-CSF) from neuropathologically diagnosed PD subjects lacking Alzheimer's disease (AD) neuropathology. In the present study, we assessed these biomarkers as well as p-tau~(181), Aβ42, and S100B by ELISA in PD (n = 43) and NC (n = 49) cases. The p-tau~(181)/Aβ42 ratio and ApoA-1 showed statistically significant differences between groups. Multiple regression analysis demonstrated that p-tau~(181)/Aβ42 had a significant odds ratio: OR = 1.42 (95% confidence interval [CI], 1.12–1.84), P = 0.006. Among the molecules investigated, intriguing correlations were observed that require further investigation. Our results suggest coexistent AD CSF biomarkers within the PD group notwithstanding that it was selected to minimize AD neuropathological lesions.
机译:鉴定可将帕金森氏病(PD)与正常对照(NC)个体区分开的生物标记物可能会提高诊断早期PD的诊断敏感性。先前的蛋白质组学研究从缺乏阿尔茨海默氏病(AD)神经病理学的神经病理学诊断的PD受试者中鉴定了死后脑室脑脊液(V-CSF)中的潜在生物标志物。在本研究中,我们通过ELISA对PD(n = 43)和NC(n = 49)病例中的这些生物标志物以及p-tau〜(181),Aβ42和S100B进行了评估。组间p-tau〜(181)/Aβ42比值和ApoA-1差异有统计学意义。多元回归分析表明,p-tau〜(181)/Aβ42具有显着的比值比:OR = 1.42(95%置信区间[CI],1.12-1.84),P = 0.006。在研究的分子中,观察到有趣的相关性,需要进一步研究。我们的结果表明,PD组中存在共存的AD CSF生物标志物,尽管选择该标志物是为了最大程度地减少AD神经病理性病变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号